A common bacterium that colonizes the stomachs of roughly half the world’s population may quietly shape how well cancer patients respond to one of modern medicine’s most powerful treatments. A new systematic review and meta-analysis, published in BMC Cancer, finds that patients infected with Helicobacter pylori who receive immune checkpoint inhibitors tend to survive for shorter periods than uninfected patients, adding a microbial twist to the already complex story of why immunotherapy works brilliantly for some people and fails for others.
Immune checkpoint inhibitors, or ICIs, have transformed the treatment landscape for melanoma, lung cancer, and many other malignancies by releasing the molecular brakes that tumors place on T cells. Yet only a minority of patients achieve durable benefit, and researchers have spent years hunting for biomarkers that predict who will respond. The gut and gastric microbiome have emerged as surprising candidates, because commensal bacteria can modulate systemic immune tone and influence how the immune system recognizes tumors. H. pylori, a pathogen adapted to persist for decades in the gastric mucosa, has been a particularly contentious player, with individual studies reporting conflicting results about its impact on immunotherapy outcomes.
To resolve that uncertainty, a team led by Zhenzhen Guo and corresponding author Shiyu Xiao of Sichuan Provincial People’s Hospital and the University of Electronic Science and Technology of China systematically searched PubMed, Embase, and the Cochrane Library for studies published up to September 2025 that reported H. pylori status alongside outcomes in cancer patients treated with ICIs. Their analysis pooled data from seventeen observational studies encompassing 3,767 patients, calculating hazard ratios for overall survival and progression-free survival and odds ratios for objective response rate, using either fixed-effects or random-effects models depending on heterogeneity across studies.
The headline finding was stark at the pan-cancer level. H. pylori infection was associated with a 58 percent higher risk of death, with a pooled hazard ratio of 1.58 and a 95 percent confidence interval of 1.21 to 2.06, and a 60 percent higher risk of disease progression, with a hazard ratio of 1.60 and a confidence interval of 1.18 to 2.16. In practical terms, infected patients on checkpoint inhibitors tended to live less long and to see their cancers advance sooner than their uninfected counterparts. The moderate heterogeneity statistics, with I-squared values of 59 percent for overall survival and 73 percent for progression-free survival, indicate that the effect varied somewhat across studies but remained broadly consistent.
Intriguingly, the bacterium’s apparent influence did not extend to whether tumors shrank. The pooled odds ratio for objective response rate was 0.79, with a confidence interval of 0.39 to 1.60, meaning there was no statistically significant difference in the probability of a measurable tumor response between infected and uninfected patients. This dissociation between response and survival is scientifically telling. It suggests that H. pylori may not primarily blunt the initial tumor-killing activity of immunotherapy, but may instead affect longer-term disease control, immune-related toxicity, or patient frailty in ways that erode survival over time. The very high heterogeneity for the response endpoint, at 80 percent, further cautions against drawing firm conclusions about response rates from the available data.
Perhaps the most striking result emerged when the researchers broke the analysis down by cancer type. In gastric cancer, the malignancy most intimately associated with H. pylori, no significant association was found between infection and any of the survival or response endpoints. By contrast, the data hinted at detrimental associations in liver cancer, esophageal squamous cell carcinoma, and melanoma, although the authors emphasize that these subgroup signals rest on limited numbers of studies and patients and should be treated as exploratory rather than definitive.
The absence of an effect in gastric cancer is more than a statistical curiosity. It raises the possibility that the relationship between H. pylori and immunotherapy outcomes is cancer-specific rather than universal. One plausible interpretation is that in gastric tumors, where the bacterium has shaped the local immune environment for years, the additional presence of infection adds little prognostic information beyond what the tumor biology already conveys. In other cancers, chronic gastric infection and the systemic inflammation it sustains may act as a background factor that subtly undermines the immune activation that checkpoint inhibitors are designed to unleash.
The meta-analysis also uncovered a methodological wrinkle with real clinical implications: how infection is defined matters. When the researchers stratified studies by whether H. pylori status referred to current infection only, or to current or past infection, the strength of the association with overall survival differed significantly between the two groups, with a p-value for subgroup difference below 0.01. This finding suggests that active infection and a history of eradicated infection may carry different prognostic weight, and it highlights a source of inconsistency in the existing literature, since studies have used serology, breath tests, stool antigens, and histology with varying thresholds to classify patients.
For clinicians, the study positions H. pylori as a candidate prognostic biomarker in cancer immunotherapy, one that is inexpensive to test for and, importantly, potentially modifiable through eradication therapy. If future research confirms that active infection drives worse outcomes, a simple course of antibiotics before or during checkpoint inhibitor treatment could become a low-risk intervention worth testing. The authors are careful, however, to note that their work does not establish causation. All seventeen included studies were observational, meaning that infected and uninfected patients may have differed in ways beyond their infection status, including age, comorbidities, antibiotic exposure, and concurrent medications, any of which could confound the apparent association.
The research team, which also included Xinyu Chen, Haoyu Peng, and Yutong Wei, and was supported by the National Natural Science Foundation of China, calls for prospective validation in specific cancer subgroups. Such studies would ideally track patients’ H. pylori status over time, standardize diagnostic methods, and distinguish current from past infection. Until then, the message for the field is one of cautious excitement: a bacterium that half of humanity carries, and that most oncologists have never considered when planning immunotherapy, may hold a measurable clue to who benefits from these drugs. Turning that clue into a clinical tool will require the kind of rigorous prospective work that this meta-analysis now makes a clear priority.
Subject of Research: Association between Helicobacter pylori infection and survival outcomes in cancer patients receiving immune checkpoint inhibitor therapy
Article Title: Association between Helicobacter pylori infection and outcomes of cancer patients receiving immunotherapy: a systematic review and meta-analysis
Article References: Guo, Z., Chen, X., Peng, H., Wei, Y., & Xiao, S. (2026). Association between Helicobacter pylori infection and outcomes of cancer patients receiving immunotherapy: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16961-9
Image Credits: AI Generated
DOI: 10.1186/s12885-026-16961-9
Keywords: Helicobacter pylori, immunotherapy, immune checkpoint inhibitors, meta-analysis, cancer prognosis, overall survival, progression-free survival, gastric cancer, microbiome, biomarker, oncology, systematic review
News Source: Nathaniel Bowman. (October 10, 2026). Common Stomach Bacterium Linked to Poorer Survival in Cancer Immunotherapy Patients. Scienmag.
